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ABSTRACT 
Background and Objective: In Italy, there is scarce evidence on the epidemiological and economic burden 
induced by the primary antibody deficiencies. The aim of this study was to elaborate the available 
epidemiological and cost data in order to estimate the annual expenditure induced by the management of 
patients affected by the common variable immunodeficiency (CVID) and X-linked Agammaglobulinemia 
(XLA) requiring an Ig replacement therapy.  
Methods: A probabilistic cost of illness model was developed to estimate the number of patients suffering 
from CVID and XLA and the economic burden associated with their therapy in terms of direct or indirect 
costs. A systematic literature review was carried out to reveal both epidemiological and economic data. 
Furthermore, a probabilistic sensitivity analysis with 5,000 Monte Carlo simulations was performed. 
Results: The epidemiological model allowed us to estimate the number of prevalent patients affected by 
XLA and CVID in Italy in 2017, corresponds to 1,885 (95% CI: 944-3,145) and 133 (95% CI: 115-152), 
respectively. The estimated total expenditure for the treatment and management of patients with CVID and 
XLA requiring an Ig replacement therapy amounts to € 42.68 million (95% CI €14.38-€86.1 million). 
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Conclusions: This set of information is supposed to provide a comprehensive perspective of the economic 
issues and facilitate better-informed public health decision-making in the management of CVID and XLA in 
Italy. 
Key Points: 
• In 2017, patients suffering from CVID and XLA in Italy were 1,885 and 133 respectively. 
• Direct costs were estimated at € 41.22 million, 94% attributable to CVID (€ 38.7 million). 
• Indirect costs accounted for € 1.5 million representing the 3.4% of total spending.
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INTRODUCTION 
Immunoglobulin (Ig) replacement therapy is the foremost treatment of the primary immunodeficiency (PIDs) 
with an antibody deficiency, a rare group of disorders presenting the failure of the immune system to 
produce sufficient antibodies in the bloodstream to combat infections [1].  
Two major antibody deficiencies, which require Ig replacement therapy, are the common variable 
immunodeficiency (CVID) and the X-linked Agammaglobulinemia (XLA) [2]. For these conditions, the Ig 
replacement therapy is effective to avoid infections and also damages induced by repeated infectious events. 
Consequently, the Ig replacement can significantly improve the survival rates and patients' quality of life [3]. 
Furthermore, different studies show that an effective therapy can significantly reduce the absenteeism from 
work or school due to the illness [3].  
In the Ig replacement therapy, a recommended range of dose between 400-600 mg/Kg body weight per 
month is commonly administered either intravenously (IVIG) every 3 or 4 weeks or subcutaneously (SCIG) 
every 1 or 2 weeks [4, 5]. Several studies pointed out that the administration of SCIG in a home setting is 
associated with an improvement of patients' quality of life [6-8], when compared with IVIG administered in 
hospital. Additionally, the intravenous administration can induce the onset of systemic adverse events during 
or after the infusion [9]. In comparison to IVIG, subcutaneous administration induces mild side effects that 
occur at the local level [10].  
In Italy, the evidence on the epidemiological and economic burden induced by the primary antibody 
deficiencies is scarce. From the economic perspective, in 2008, Matucci et al. [11] published a cost 
minimization analysis, which provided a thorough estimate of the mean cost per patient suffering from CVID 
and treated with either IVIG or SCIG. As a result, the less costly alternative was the SCIG (€ 15,192 per 
patient), corresponding to a 12.7% lower than the alternative IVIG (€ 17,409 per patient). This was mainly 
due to higher consumption of resources (medical, nursing and ambulatory) associated with the intravenous 
administration.  
From the epidemiological point of view, the prevalence of PIDs in Italy is on average the same as other 
European countries [12]. In May 2014, 1,120 Italian patients with PIDs were recorded, considering the 
Italian registry IPINET (Italian Primary Immunodeficiencies Network) and the registry AIEOP (Italian 
Association of Pediatric Hematology Oncology). However, this is not the real amount of Italian people 
affected by PIDs, as not all patients with PIDs are included in current registers, especially for those primitive 
immunodeficiencies affecting the adult population, such as the common variable immunodeficiency (CVID) 
[2, 9].  
The development of new technologies that improve the diagnostic and treatment accuracy for people with 
rare diseases is living a bright moment. However, to assure that the best quality of evidence-based care and 
treatment is offered to patients, the collection of reliable health data is compulsory. Although they seem to be 
associated with a considerable economic burden [13], cost of illness information on rare diseases is very 
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limited, especially in Italy [14]. These kinds of information are of primary importance for public health 
decision makers to provide proper healthcare services, to establish whether a new technology deserves to be 
introduced and finally to allocate adequate funds. With a cost-of-illness procedure, a systematic evaluation of 
economic consequences of a given disease in the health system is performed. 
The objective of the study is to estimate the annual economic burden related to the management of patients 
requiring an Ig replacement therapy (specifically patients affected by CVID and XLA) from the societal 
perspective (i.e. direct and indirect health care costs). 
1. METHODS 
2.1 Design of the study 
In order to estimate the annual costs caused by patients with PIDs requiring Ig replacement therapy, a 
probabilistic cost of illness model capable of estimating the number and distribution of patients suffering 
from CVID and XLA was developed. According to the purpose of the study, direct and indirect costs were 
estimated. To assess direct medical costs, the model was informed with data obtained from  a systematic 
literature review. A Bottom-Up approach was implemented [15-17] multiplying the average cost per patient 
by the disease prevalence to estimate direct costs associated with the patient’s management. The average 
direct medical cost of administration of Ig (both IVIG and SCIG) was quantified according to the different 
management practices used in the two diseases considered.  
Indirect costs were assessed with the Human Capital Approach on the basis of data provided by the Italian 
Association for Primary Immunodeficiency (AIP). This method appraises costs in terms of loss of 
productivity taking into account the expected future earnings lost due to the disease [15-17]. 
 
2.2 Systematic literature review 
A systematic literature review was carried out to identify the main parameters required to model the natural 
history of the diseases looking at epidemiological and/or economic evaluation studies concerning CVID, 
XLA and Ig replacement therapy in Italy. 
The systematic literature review was conducted using the following scientific search databases: MEDLINE 
(PubMed), Cochrane Library, Health Technology Assessment on the Net, Clinical trial. gov, European 
Medicines Agency (EMA), Italian Medicines Agency (AIFA), Italian National Agency for Regional Health 
Services (Age.na.s), Italian National Institute of Statistics (ISTAT), Italian National Institute of Health, 
[EpiCentro (the epidemiological web site dedicated to public health)], ResearchGate, National and 
International associations of physicians and patients (ESID, AIEOP, AIP). Moreover, the following Italian 
journals of health economics were examined: PharmacoEconomics Italian Research Article (Springer), 
Farmeconomia e Percorsi Terapeutici (JournalSeek), Global and Regional Health Technology Assessment 
(Wichtig), Quaderni dell'Italian Journal of Public Health. Peer-reviewed journals, conferences, congresses 
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and other available Internet sources were monitored up to June 2017 for presentations or communications of 
further information. 
The research focused on papers published between 2007 and 2017 in Italian or English. The research was 
organized in two macro subjects: the epidemiological issues concerning XLA and CVID and the economic 
aspects related to the costs incurred by NHS as well as the society.  
The systematic literature review process was organized in four steps: identification, screening, eligibility and 
inclusion (consistently with the recommended guidelines for the systematic analysis of scientific literature 
[18, 19]. The key words used for the scientific literature-scanning were as follows: primary 
immunodeficiency, primary antibody deficiencies, common variable immunodeficiency, CVID, 
Agammaglobulinemia, XLA, Cost of Illness, Cost-Benefit Analysis, Health Technology Assessment (HTA), 
Cost-Effectiveness Analysis, Cost-Utility Analysis, Economic Evaluation, Epidemiology, Prevalence. See 
Supplementary Material for details. 
For the inclusion, two researchers independently reviewed the studies looking at the title, the abstract or the 
full text. Results have been compared afterword; any disagreement and risk of bias were solved through a discussion between the authors.   The differences were discussed and solved through analyses 
and a confrontation with other experts. All the studies used to determine the epidemiological and economic 
parameters had to meet at least one of the following inclusion criteria:  
1. refer to epidemiological data (with particular attention to the prevalence and distribution of treated 
patients) searched in population databases, national surveys or registries; 
2. refer to clinical studies concerning the patterns of treatment for CVID and XLA; 
3. refer to economic evaluations, and Health Technology Assessments including the cost of the Ig 
replacement therapy in patients with CVID or XLA;  
4. refer to relevant studies concerning adverse events due to the Ig replacement therapy. 
All other economic or epidemiological studies which were not meeting the above mentioned inclusion 
criteria were excluded. At the end of the systematic literature review process, 8 epidemiological/clinical 
(table 1 and 2) and 3 economic (table 3) papers were selected, respectively (figure 1).  
2.3 Epidemiological and Clinical Parameters 
Despite the lack of information and the underlying uncertainty concerning the epidemiology of PIDs, in the 
present study, we attempted to estimate the actual number of patients suffering from XLA and CVID in Italy. 
The summary of clinical and epidemiological information drawn from the scanned databases is shown in 
table 1 and table 2. Additional information was provided by a panel of expert clinicians (Expert opinion). 
The expert panel also validated inputs to inform the model. 
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To overcome the lack of published data, the number of patients with XLA was estimated using an average 
prevalence value drawn from European registries. In particular, since data included in the Italian registry for 
XLA (AIEOP) were not reported in a publication, prevalence values calculated in France [20] and the UK 
[21] were taken into account. The choice was made in accordance with the opinion of ESID regarding the 
validity of French registries and due to the socio-demographic similarities between UK and Italy.  
As registries did not contain reliable estimations of diagnosed patients, the number of individuals suffering 
from CVID was calculated as follows:  
1. the minimum value was derived from the prevalence of CVID reported in the UK registry [21];  
2. the maximum value was estimated considering the overall prevalence of PIDs [22] multiplied by the 
frequency of CVID observed among the PIDs [23] and multiplied by the rate of patients diagnosed 
in Italy [Expert Opinion]; 
3. the central value of distribution was calculated on the basis of the two extremes. 
In order to assess the Ig consumption, patient characteristics such as age, weight, dosage, frequency of 
treatment, and the utilization of Ig derived by contract manufacturing were considered.  
Five regimens of Ig replacement therapy were individualized: IVIG at 5% dosage, IVIG at 10% dosage, 
SCIG at 16% dosage, SCIG at 16.5% dosage and SCIG at 20% dosage [24, 25]. 
The ISTISAN report [24] indicates that 81% of patients receiving IVIG at 5% dosage is treated with plasma-
derived products. These patients were excluded from the computation because actually the cost of this 
treatment is not known.    
2.4 Cost Parameters 
Direct cost data associated with each Ig replacement therapy were identified. The costs were actualized to 
2017 and parametrised for comparison with the Price Index for monetary revaluation by ISTAT [26]. Data 
were related to the annual management of XLA and CVID including the cost of: Immunoglobulins, 
premedication, adverse events, administration, and diagnostic procedures. To reflect the variability between 
different Regional Health Services, a range for each parameter (corresponding to 15%) was built. The details 
concerning the parameters and probabilistic ranges used in the model are indicated in table 3.  Most of the 
cost parameters were derived from the paper published by Matucci [11], with the exception of the cost of Ig 
and adverse events occurring with subcutaneous therapy. As far as prices are concerned, those commonly 
charged to the Italian NHS, including net discount rates specified by law [27], were considered.  
The cost of adverse events was calculated on the basis of the utilization of 2 grams of the most frequently 
used drugs in these circumstances (i.e. betamethasone dipropionate and dexchlorpheniramine maleate) [28] 
for an average duration therapy of two days [29]. 
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2.5 Indirect costs 
At the moment, there is no information about the loss of productivity caused by XLA or CVID. Therefore, 
some information was collected by the AIP (table 3), counting: percentage of patients who loses work hours 
due to infusion (SCIG), work hours lost per patient (SCIG), work days lost per patient (IVIG). This 
information was interpolated with hourly labour cost corresponding to €21.4 (estimation by EUROSTAT) 
[30]. Starting from these data, the value of a daily work amounts to €154 corresponding on average to 7 
hours worked per day (36 hours worked per week in 5 days). The minimum value corresponded to 6 hours 
worked per day on average, while the maximum value to 8 hours worked per day on average. To estimate 
indirect costs and those associated with mortality, it was conservatively assumed that only a proportion of 
patients (57.7%) is employed and in productive age.  
2.6 Statistical Analysis 
In order to consider the variability of data used to inform the model, a Probabilistic Sensitivity Analysis 
(PSA) was performed. The analysis consists in using the differences found in the examined sources 
indicating a minimum and maximum value of the uncertainty distribution of each parameter. 
The probabilistic distribution was attributed applying what is generally reported for the development of 
economic evaluation models, distinguishing between costs (gamma distribution) and epidemiological 
parameters (beta distribution) [31]. Furthermore, the distribution of each parameter was used to perform 
5.000 Monte Carlo simulations in order to obtain interval estimates [95% Confidence Interval (CI)] of the 
main epidemiological and economic data. 
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3 RESULTS 
The epidemiological model allowed us to estimate the number of prevalent patients affected by XLA and 
CVID in Italy in 2017. This estimate corresponds to 1,885 (95% CI: 944-3,145) and 133 (95% CI: 115-152) 
patients suffering from CVID and XLA, respectively. On a total of 2,017 patients (95% CI: 1,065-3,369), 
86.2% commonly receive an Ig replacement therapy. The estimated patients were categorized by route of 
administration (SCIG and IVIG) and dosage (figure 2). The mean annual direct cost incurred by the Italian 
NHS for patient (with XLA and CVID) treated with SCIG and IVIG is equal to € 21,649 (95% CI: €7,812-
€42,757) and € 25,801 (95% CI: €11,134 - €43,403), respectively. The difference of approximately €4,000 is 
mainly associated with the acquisition cost of Immunoglobulins. This is also confirmed when the distribution 
cost by disease (XLA and CVID) is analysed (figure 3). On average, about 80% of the total expense is 
absorbed by the acquisition cost of drugs.  
The total direct cost incurred by the Italian NHS for patients affected by CVID and XLA is shown in table 4. 
The probabilistic model estimates an economic annual burden for direct costs corresponding approximately 
to € 41.22 million (95% CI: €13.54 - €84.06 million): 6% is pertaining to XLA [€ 2.5 million (95% CI: 
€1.15-€4.34 million)], while the majority is due to CVID [€ 38.7. million (95% CI: €11.59-€81.94 million)]. 
Tables 4 and 5 describe in detail either direct or indirect costs associated with the route of administration and 
dosage. As regards total indirect costs, they account for about € 1.5 million (95% CI: €0.47-€2.99 million), 
representing the 3.4% of total spending. The estimated total expenditure for the treatment and management 
of patients with CVID and XLA requiring an Ig replacement therapy amounts to € 42.68 million (95% CI: 
€14.38-€86.1 million). Large majority of this expense (94%) is attributable to patients with CVID, which is 
the most common condition that requires the most expensive therapy.  
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4 DISCUSSION  
This is the first study in which direct and indirect costs (incurred by either the NHS or the society) were 
taken into account to estimate the overall burden of some of the most frequently reported PIDs requiring an 
Ig replacement therapy in our country. The results provide new insights for which there was scarce or 
fragmented evidence in the previous literature. 
The economic yearly burden induced by patients requiring an Ig replacement therapy in 2017 was estimated 
at a value just over € 42.7 million. Most of this expense (94%) is attributable to patients with CVID, which is 
the most widespread condition with the most expensive therapy. The higher cost of treatment is associated 
mainly with adult patients suffering from CVID, with a higher body weight and therefore with a greater 
consumption of Ig. 
The developed model shows that indirect costs exceed € 1.5 million, corresponding to about 3.4% of total 
costs. However, it should be borne in mind that these indirect costs do not take into account the presenteeism 
and the loss of productivity of caregivers. These two types of indirect costs express the extent of productivity 
losses and the relative amount might be remarkable, especially for patients with XLA. It is also noteworthy 
to mention that presenteeism may actually be a much costlier problem than absenteeism (approximately 3-10 
times higher) [32, 33]. Furthermore, presenteeism is quite common in tough economic times, when 
employees may be extremely afraid of losing their job [34]. 
The epidemiological model estimates 2,017 patients are supposed to be currently affected by CVID and 
XLA. In 2014, 1,020 Italian patients affected by PIDs with antibody deficiency were recorded in the ESID 
registry, whereas the patients estimated by our model is about twice, considering only CVID and XLA. This 
could be caused by several factors, including incomplete recordings, failure to update and missing patients. 
Our estimates however, are consistent with the inputs used in another important registry [12, 35].  
The Ig intravenously administered are more expensive than SCIG, with a difference of about €4,000 per 
patient, due to a higher cost for administration as well as indirect costs. These figures are consistent with data 
recently published in a nationwide study [11]. In spite of a greater cost, the preponderance of patients in Italy 
is treated with IVIG regardless the disease type.  
The SCIG therapy for PIDs has an equal efficacy compared to IVIG, induces fewer systemic reactions, and 
may be self-infused; but on the other hand, requires multiple infusion sites, more frequent infusions, and 
dose adjustment to achieve pharmacokinetic equivalence [36]. To solve these problems, new treatments 
might be useful, as immunoglobulins facilitated with rHuPH20 (recombinant human hyaluronidase) that 
increases tissue permeability and facilitates dispersion and absorption, enabling administration of monthly 
doses in one site with the option of home-based self-administration [36]. This type of Ig should generate the 
reduction of the overall costs associated with the administration, the management of adverse events, the cost 
of wasting, and also an improvement of patients’ quality of life.   
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This study has some limitations. Firstly, the true prevalence of CVID and XLA is uncertain because the 
model was not informed with complete epidemiological Italian data. This is due to the impossibility to 
identify a unique national body in charge of recording costs and epidemiological data concerning these 
diseases. At present, a specific prevalence study conducted on representative sample of the Italian population 
is lacking and data drawn from local registries are unpublished. Therefore, it was necessary to calculate the 
estimates of the main epidemiological indicators using some of the European registries [21, 22].  
However, the systematic literature review, performed according to rigorous international guidelines, allowed 
to identify the most recent, accurate, and homogenous data sources that are well-acknowledged by the 
scientific community. The same very well-validated methodological sequence has already been implemented 
to measure the clinical and economic burden of different pathological conditions such as HPV- and HCV-
induced diseases in Italy [37, 38]. Furthermore, probabilistic sensitivity analysis was purposely carried out to 
obtain solid interval estimations, considering the heterogeneity of the available data and the overall 
uncertainty of the sources used.  
Secondly, due to scarce or missing information, it was not possible to estimate some expense items 
associated with the diseases of interest. As a consequence, results tend to underestimate the overall economic 
burden. This is particularly significant in regard to indirect costs. Only the loss of productivity of patients 
suffering from CVID and XLA was considered. However, a Cost of Illness evaluation should take into 
account the full range of indirect costs, including the loss of productivity and competitiveness associated 
with the presenteeism, the loss of productivity of caregivers and finally early retirements induced by the 
diseases. There is another motivation that surely contributed to underestimate current results. According to a 
rigorous implementation of methodological procedures, expenses related to the treatment of patients 
receiving IVIG 5% [i.e. 144 (95% CI: 73-246 patients)] were excluded from the computation of the 
economic burden. Indeed, the direct cost incurred by Regions for plasma-derived products (due to contract 
manufacturing) is commonly unrevealed or just partially declared. This condition is expected to change soon; 
but at this moment in time these costs were basically omitted since they were unidentified.  
Finally, the direct health costs were calculated on the basis of data elaborated from the Careggi’s 
Immunoallergology Centre in Florence [11]. Although results provided by this study are statistically robust, 
they cannot be considered fully representative of the national health context.   
5 CONCLUSION: 
In conclusion, the present study aimed at filling the information gap concerning the epidemiological and 
economic burden associated with patients affected by CVID and XLA. This set of information is supposed to 
provide a comprehensive perspective for an enhanced understanding of the most relevant economic issues 
and facilitate better-informed public health decision-making in the management of these PIDs in Italy. 
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 Table 1 - Epidemiological parameters related to patients with XLA and CVID requiring an Ig replacement therapy 
Clinical parameter Base-case Minimum Maximum Source DISTRIBUTION ALPHA BETA 
Epidemiological parameters CVID        
Prevalence*100.000 3.17 1.27 5.07 [21, 22] BETA 8.91 700.366 
Treated with IG 85.0% 78.0% 92.0% [2] BETA 84.97 13.99 
% IVIG 69.5% 60.0% 79.0% [2] BETA 62.71 26.52 
% IVIG 5 62%   Expert opinion    
% IVIG 10 38%   Expert opinion    
% SCIG 30.5% 21.0% 40.0% [2] BETA 27.52 61.71 
% SCIG 16 34.0%   Expert opinion    
% SCIG 16.5 13.0%   Expert opinion    
% SCIG 20 53.0%   Expert opinion    
Contract manufacturing 81.0%   [24]    
Epidemiological parameters XLA        
Prevalence*100.000 0.22 0.19 0.25 [20, 21] BETA 0.71 378.673 
Treated with IG 91.5% 88.9% 94.0% [2] BETA 422.44 38.50 
% IVIG 66.5% 60.0% 73.0% [2] BETA 134.70 66.86 
% IVIG 5 62%   Expert opinion    
% IVIG 10 38%   Expert opinion    
% SCIG 33.5% 27.0% 40.0% [2] BETA 67.86 133.70 
% SCIG 16 34.0%   Expert opinion    
% SCIG 16,5 13.0%   Expert opinion    
% SCIG 20 53.0%   Expert opinion    
Contract manufacturing 81.0%   [24]    
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous immunoglobulin, SCIG: Subcutaneous immunoglobulin, 
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Table 2- Clinical parameters related to patients with XLA and CVID requiring an Ig replacement therapy 
 
 
Age of CVID patients (2014) Base-case Minimum Maximum Source DISTRIBUTION ALPHA BETA 
>12 9.0% 27.0% 10.0% [2] BETA 283.16 2.862.11 
13 - 17 8.0% 11.0% 8.0% [2] BETA 25.13 288.02 
18 - 29 19.0% 15.0% 12.0% [2] BETA 70.21 298.31 
30 - 44 21.0% 18.0% 16.0% [2] BETA 148.71 558.43 
45 - 64 30.0% 25.0% 39.0% [2] BETA 29.88 68.72 
< 65 13,0% 4,0% 15,0% [2] BETA 141,21 944,00 
Age of XLA patients (2014)        
>12 35.0% 27.0% 10.0% [2] BETA 47.79 87.76 
13 - 17 18.0% 11.0% 8.0% [2] BETA 20.83 93.89 
18 - 29 30.0% 15.0% 12.0% [2] BETA 10.76 24.10 
30 - 44 13.0% 18.0% 16.0% [2] BETA 22.59 150.20 
45 - 64 4.0% 25.0% 39.0% [2] BETA 0.13 2.21 
< 65 0.0% 4.0% 15.0% [2] BETA 0.00 1.20 
Body weight by age (2014)        
>12 21.90 11.45 48.20 [2] GAMMA 2.66 8.22 
13 - 17 61.95 43.95 91.15 [2] GAMMA 17.29 3.58 
18 - 29 73.20 54.50 105.05 [2] GAMMA 20.29 3.61 
30 - 44 78.05 60.60 110.30 [2] GAMMA 22.50 3.47 
45 – 64 81.20 61.90 109.70 [2] GAMMA 31.18 2.60 
< 65 76.05 57.60 97.85 [2] GAMMA 46.75 1.63 
Ig dosage by administration (mg/Kg)       
IVIG  382 187 546 [2] GAMMA 20.84 18.33 
SCIG 105 48 179 [2] GAMMA 7.73 13.58 
Treatment frequency (per year)        
IVIG 15 13 26 [2, 9] GAMMA 7.14 2.10 
SCIG 54 24 104 [2, 9] GAMMA 12.45 4.34 
Premedication/Adverse Events        
Patients receiving premedication (IVIG) 42%       
Incidence AE (SCIG) 75%   [29, 39]    
% treated adverse events 25%   Expert opinion    
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous immunoglobulin, SCIG: Subcutaneous immunoglobulin, AE: adverse events,  
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Table 3 - Direct and indirect costs induced by patients with XLA and CVID requiring an Ig replacement therapy 
Direct cost parameter per patient Base-case Minimum Maximum Reference DISTRIBUTION ALPHA BETA 
IVIG        
Cost of Ig 5% (€/g)  € 47.88   [27]    
Cost of Ig 10% (€/g) € 49.80   [27]    
Cost for medical and nurse staff (per administration) € 135.3 € 115.0 € 155.6 [11] GAMMA 179.73 0.79 
Cost for ambulatory (per administration) € 179.8 € 152.85 € 206.80 [11] GAMMA 170.74 1.05 
Cost of premedication (per administration) € 1.05 € 0.90 € 1.21 [11] GAMMA 170.74 0.01 
Cost of diagnostic examination procedures (per year) € 274.9 € 233.7 € 316.1 [11] GAMMA 170.74 1.61 
SCIG        
Cost of Ig 16% (€/g) € 47.88   [27]    
Cost of Ig 16.5% (€/g) € 47.88   [27]    
Cost of Ig 20% (€/g) € 50.40   [27]    
Cost for infusion pumpa (per year) € 348.10 € 295.89 € 400.32 [11] GAMMA 170.74 2.04 
Cost of the materials for infusion (per administration) € 16.82 € 14.30 € 19.35 [11] GAMMA 170.74 0.10 
Cost of AE (per administration) € 0.76 0.73 € 0.80 € Calculation GAMMA 1.386.82 0.001 
Cost of diagnostic examination procedures (per year) € 274.9 € 233.7 € 316.1 [11] GAMMA 170.74 1.61 
Indirect cost parameter  Base-case Min Max Reference DISTRIBUTION ALPHA BETA 
Day labour cost per patient € 154 € 128 € 180 Calculation. [30] GAMMA 138.30 1.11 
Hourly labour costs  per patient € 21.4 € 16.0 € 26.7 [30] GAMMA 61.47 0.35 
% of people who lose work hours for infusion (SCIG) 24%     AIP      
lost hours per patient SCIG 1.37 1.0 2.5 AIP GAMMA 5.59 0.24 
days lost per patient IVIG 1.01 0.50 1.43 AIP GAMMA 21.77 0.046 
Employment rate  58.1%      [40]    
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous immunoglobulin, SCIG: Subcutaneous immunoglobulin, AE: Adverse events  
a - Cost of the main infusion pump (Crono S-PID ®) used for SCIG administration in Italy 
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Table 4- Direct costs associated with the IG administration in € million (Minimum- Maximum)  
XLA 
IVIG 5% IVIG 10% SCIG 16% SCIG 16.5% SCIG 20% 
€ 0.20 € 1.52 € 0.23 € 0.09 € 0.38 
(€0.07-€0.39) (€0.52-€3.04) (€0.07-€0.49) (€0.03-€0.19) (€0.12-€0.79) 
Total cost XLA IVIG Total cost XLA SCIG 
€ 1.77 € 0.72 
(€0.61-€3.53) (€0.23-€1.48) 
Total cost XLA 
€ 2.49 
(€1.15-€4.34) 
CVID 
IVIG 5% IVIG 10% SCIG 16% SCIG 16.5% SCIG 20% 
€ 2.60 € 25.26 € 3.38 € 1.29 € 5.53 
(€0.54-€6.28) (€5.74-€58.95) (€0.7-€8.14) (€0.27-€3.11) (€1.14-€13.32) 
Total direct cost CVID IVIG Total cost CVID SCIG 
€ 28.53 € 10.21 
(€6.49-€66.57) (€2.11-€24.57) 
Total cost CVID 
€ 38.73 
(€11.59-€81.94) 
Total direct cost 
€ 41.22 
(€13.54-€84.06) 
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous 
immunoglobulin, SCIG: Subcutaneous immunoglobulin 
Table 5 - Indirect costs associated with the IG administration in € million (Minimum- Maximum) 
XLA CVID 
IVIG SCIG IVIG SCIG 
€ 0.05 € 0.02 € 1.07 € 0.31 
(€0.02-€0.1) (€0.003-€0.04) (€0.28-€2.39) (€0.04-€0.86) 
Total indirect cost XLA Total indirect cost CVID 
€ 0.07 € 1.38 
(€0.03-€0.13) (€0.43-€2.89) 
Total indirect cost 
€ 1.45 
(€0.47-€2.99) 
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous 
immunoglobulin, SCIG: Subcutaneous immunoglobulin 
 
  
18 
 
Figure 1 - PRISMA Flow diagram 
Figure 2 - Number of patients by disease (CVID and XLA) and route of administration per year (2017) 
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous 
immunoglobulin, SCIG: Subcutaneous immunoglobulin 
Figure 3- Annual average cost per patient requiring an Ig replacement therapy 
XLA:  X-linked agammaglobulinemia, CVID:  Common variable immunodeficiency, Ig: Immunoglobulin, IVIG: Intravenous 
immunoglobulin, SCIG: Subcutaneous immunoglobulin, AE: Adverse events, pts: patients 
 
 
 
 
 
